IDEAYA Biosciences, Inc. (IDYA) - Form 8-K Summary
Business Context and Reporting Period
IDEAYA Biosciences, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 5, 2025. The filing announces the financial results for the second quarter ended June 30, 2025. The company's common stock trades on The Nasdaq Global Select Market under the symbol IDYA.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for these metrics.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text, as the specific financial results are contained within the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, management commentary, risks, or unusual items are described in the text of this Form 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 5, 2025) for actual Q2 2025 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company has issued any forward-looking guidance for the remainder of 2025.